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I n t r o d u c t i o n  
Expenditures by anesthesia providers may represent  3% to 5% of the total U.S. 
health care costs of  $800 billion.~ These costs include preoperative laboratory 
evaluations, cost of  equipment,  salaries of  anesthesia providers and support  
personnel,  and cost of  pharmacologic drugs. At the University of  Michigan 
Medical Center, 54% of the Depar tment  of  Anesthesiology's budget  went for 
salaries (Figure 1), which concurs with other reports in the literature. ~ The 
other  major expenditure was for pharmacy charges. At our  institution, the 
total pharmacy charges per  anesthetic were approximately $75. Half  of  these 
charges were for two classes of  drugs: volatile anesthetic drugs and neuromus- 
cular blocking drugs (Figure 2). In the interest of  curbing continuing increases 
in expenses, a quality improvement  team was formed to study the use of  
volatile anesthetics in the operating rooms of the Adult General Hospital. 
Quality improvement,  or total quality management  (TQM), is a concept  
taken f rom the work of W. Edwards Deming. s The  principles of  TQM are now 
being applied to the practice of  medicine. As implemented at the University 
of  Michigan, the team process involved seven steps designed to determine 
the root cause of  a problem and to formulate an appropriate response. The  
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Anesthet ic  Costs 
• drugs 24% 
[ ]  salaries 54% 
- -  depreciation 4% 
consumables 10.5% 
misc 7.5% 
Figure 1. Anesthetic department budget by category. Data 
from fiscal year 1992-93. Total budget was $6,376,617. 
Drug Costs 
• volatile 25% 
• nmb 26% 
• benzodiazepines 8% 
[ ]  barbiturate 6,6% 
[ ]  propofol 6% 
• narcotics 3.4% 
• other 25% 
Figure 2. Pharmacy charges by category. Data from fiscal 
year 1992-93. Total charges were $1,216,446. nmb = neuro- 
muscular blocking drugs. 
sequence of efforts within the seven steps was as follows: 
(1) identification of a theme that would describe our 
problem and opportunity for change; (2) determination 
of an indicator that would enable our tracking of prog- 
ress; (3) characterization of the current situation, written 
as a clear, concise problem statement; (4) cause-and- 
effect analysis, leading to the discovery of root causes of 
the problem; (5) evaluation of  possible countermeasures, 
systematically looking for the measures that would yield 
the greatest effect for the effort; (6) implementation of 
countermeasures to determine effectiveness; (7) estab- 
lishment of  practice guidelines and continued monitor- 
ing of countermeasures. 
Applying steps 1 through 4 resulted in the following 
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hypothesis: application of educational countermeasures 
(publication of drug costs to the faculty and at the site 
of use, instruction in low-flow anesthetic technique, and 
teaching rational selection of neuromuscular blocking 
drugs) will decrease the per case cost of the following 
drugs: volatile anesthetics, neuromuscular blocking 
drugs, and nitrous oxide (N20). This study reports the 
results of applying these principles of cost containment 
to anesthetic drugs. 
Materials and Methods  
Educational intervention consisted of multiple steps, in- 
cluding (1) listing all drug and supply costs on a central- 
ized database accessible to all faculty members via a 
computer server and at the site of use (anesthesia carts); 
(2) a formal lecture on the conduct of  low-flow anesthe- 
sia, delivered in October 1992, which served as the cate- 
gorical division between "before" and "after"; (3) 
equipping each operating location with a drug analyzer 
to facilitate the teaching of low-flow and closed-circuit 
anesthesia; (4) discussion of cost at each morning's pre- 
anesthetic conference; (5) discussion of cost contain- 
ment measures at faculty meetings; and (6) intensive one- 
on-one teaching of low-flow anesthetic techniques and 
principles of uptake and distribution. Low-flow anesthe- 
sia was defined as flows at or below 1.5 L /min  after 30 
minutes of anesthesia. 
Concurrent with cost containment efforts aimed at 
decreasing volatile anesthetic use via low-flow delivery 
techniques, efforts were made to decrease the per case 
cost of neuromuscular blocking drugs. Initial surveys in- 
dicated that average vecuronium use was as high as one 
vial (10 mg) per case. To decrease waste of neuromuscu- 
lar blocking drugs, residents were discouraged from rou- 
tine preparation of  neuromuscular blocking drugs and 
encouraged to fracfionate the dose into several syringes 
to enable use among several patients without risk of con- 
taminafion. Additionally, given that the average case du- 
ration at the Adult General Hospital was 2.9 hours and the 
duration ofvecuronium is well under 1 hour, vecuronium 
should not be the drug of choice for muscle relaxation 
at the University of Michigan. Pancuronium has a dura- 
tion of action compatible with a case of 3 hours'  duration 
and a cost per case one-tenth that ofvecuronium. There- 
fore, suggestions were made that, unless the patient had 
a contraindicafion to pancuronium, it should be the drug 
of choice for neuromuscular relaxation. All final deci- 
sions were made by the attending staff anesthesiologist. 
The form of anesthesia and the drugs to be used were 
always at the discretion of the staff anesthesiologist. 
Data were collected by a retrospective analysis of  order- 
ing for the following drugs: isoflurane, enflurane, pan- 
curonium, vecuronium, atracurium, and N20. Case data 
were obtained from the departmental billing office. For 
volatile drugs and neuromuscular blocking drugs, each 
month's  ordering costs were totaled, then the total was 
divided by the cases in that month. For N20, which 
was delivered in bulk on a quarterly basis, each delivery 
was divided by the preceding 3 month 's  caseload. Total 
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cost  o f  c o m m o d i t i e s  was d iv ided  by the  case load  to deter-  
m ine  the  total  cost  p e r  case o f  c o m m o d i t i e s  on  a yearly 
basis for  1989 to 1993. Qual i ty  assurance  (QA) da ta  were 
o b t a i n e d  f rom Apr i l  1991 to N o v e m b e r  1993 to t rack the 
o c c u r r e n c e  o f  r e i n tuba t i on  as an ind ica to r  o f  i nadequa t e  
reversal  o f  n e u r o m u s c u l a r  b lock ing  drugs.  
Costs were s t andard ized  at  a p e r  un i t  rate  for  the  
du ra t i on  o f  the  study as follows: p a n c u r o n i u m ,  $1 .63 /10  
mg; vecuron ium,  $17 .70/10  mg; a t racur ium,  $37.80/100 
mg; isoflurane,  $88.97/100 ml; enf lu rane ,  $150.13/250 
ml; N20,  $0 .49 /cub ic  foot; p ropofo l ,  $9 .51/200  m g  o r  
$24.78/500 mg. S tandard iza t ion  o f cos twas  d o n e  to study 
changes  in ut i l izat ion r a the r  than  cost  p e r  se, as cost  may 
have var ied  with supp l i e r  o r  over  the  t ime course  o f  the  
study. 
Statistical analysis was by u n p a i r e d  t-test for  g roups  
e i the r  be fo re  O c t o b e r  1992 o r  af ter  O c t o b e r  1992. Signifi- 
cance  was set  a t  p < 0.05. Data  a re  r e p o r t e d  as means  _ 
SEM. The  n indicates  the  n u m b e r  o f  m o n t h s  s tud ied  for  
volat i le  drugs ,  p ropofo l ,  a n d  n e u r o m u s c u l a r  b lock ing  
drugs ,  or, in the  case o f  N~O, the  n u m b e r  o f  deliveries.  
Resul t s  
To d e t e r m i n e  the effect  o f  educa t iona l  in te rven t ions  on  
volat i le  anes the t ic  use, a basel ine  was es tabl ished by re t ro-  
spective analysis o f  the  15 m o n t h s  p r i o r  to O c t o b e r  1992. 
Dur ing  this t ime,  the  p e r  case cost  o f  volati le anes thet ics  
at  the  Main Hosp i ta l  was $19.20 + 1.16 (n = 15). In  
the  14 m o n t h s  fol lowing the educa t iona l  in te rvent ions ,  
volat i le  anes the t ic  p e r  case cost  dec reased  significantly 
to $15.16 + 0.39 (n = 14) (p = 0.0034; Figure 3). This 
r ep resen t s  a decrease  o f  $4.04, o r  21%, p e r  case. 
Mul t ip l ied  by a case load  o f  app rox ima te ly  16,000 cases 
p e r  year, this results in a savings o f  m o r e  than  $60,000 
p e r  year. 
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Figure 3. Cost of  volatile anesthetics before and after inter- 
vention. *p < 0.05. 
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Figure 4. Cost of  nitrous oxide before and after interven- 
tion. *p < 0.05. 
As a check  agains t  o t h e r  d rugs  be ing  subst i tu ted  for  
volati le anesthet ics ,  p ropo fo l  use also was t racked  and  
showed no  s ignif icant  change  over  the  study p e r i o d  
(p = 0.1926). As a fu r the r  con f i rma t ion  o f  these reduc-  
t ions in volati le anes the t ic  use be ing  a t t r ibu tab le  to low- 
flow anes the t ic  techniques ,  the  p e r  case ut i l izat ion o f  
N20 was investigated.  This  also showed a r educ t ion  in 
cost  p e r  case, f rom $0.907 _+ 0.044 (n = 6) to $0.707 
_+ 0.069 (n = 4), o r  22% (p = 0.325; Figure 4). 
Efforts to decrease  the  cost  p e r  case o f  n e u r o m u s c u l a r  
b lock ing  drugs  also were successful. The  p r ima ry  effor t  
was toward the subst i tu t ion o f  p a n c u r o n i u m  for  vecuro-  
n ium when  the re  was no  con t r a ind ica t ion  and  anes thes ia  
t ime was g rea te r  than  90 minutes .  Fol lowing these mea-  
sures, a m a r k e d  r educ t ion  in total  cost  for  n e u r o m u s c u l a r  
b lock ing  drugs  was n o t e d  af ter  O c t o b e r  1992. Cost p e r  
case dec reased  f rom $19.67 _ 1.35 (n = 3) to 12.23 _+ 
0.66 (n = 14), a r educ t ion  o f  near ly  38% (p = 0.003; 
Figure 5). Mult ip l ied  by the caseload,  this f igure  represen ts  
a savings o f  near ly  $120,000 in an annua l  budget .  
As a decrease  in cost  p e r  case o f  volat i le  anesthet ics ,  
N20,  and  n e u r o m u s c u l a r  b lock ing  drugs  may be  due  to 
a decrease  in the  pe rcen t age  o f  cases d o n e  as gene ra l  
anesthet ics ,  we ca lcu la ted  the  pe rcen tage  o f  cases d o n e  
as gene ra l  anes thet ics  in the  before  a n d  af ter  per iods .  
These  da ta  show tha t  the  pe rcen t age  o f  genera l  anes- 
thet ic  cases increased  f rom 71.3% _+ 0.5% ( n =  15) to 
75.2% _+ 0.6% (n = 14) ( p <  0.0001). 
QA da ta  r ega rd ing  possible  compl ica t ions  o f  these 
measures ,  specifically re in tuba t ion ,  were inconclusive.  In  
the 14 mon ths '  wor th  o f  available da ta  p r e c e d i n g  the 
i m p l e m e n t a t i o n  of  cost  c o n t a i n m e n t  measures ,  the re  
were 13 r e in tuba t ions  in the Adu l t  Genera l  Hospi ta l ,  
resul t ing  in a f requency  o f  0.066% (13 re in tuba t ions  ou t  
o f  19,739 cases).  P a n c u r o n i u m  was involved in 3 re intu-  
bat ions,  v e c u r o n i u m  in 3, a n d  succinylchol ine  in 2. Data  
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Cost of Neuromuscular Blocking Drugs per Case 








Figure 5. Cost of neuromuscular blocking drugs before and 
after intervention. *p < 0.05. 
to determine which neuromuscular blocking drug was 
used were lacking in 5 charts. For the 11 months '  worth 
of available data after implementation, there were 10 
reintubations out of 14,927 cases, resulting in a frequency 
of 0.067%. Of these 10 cases, 2 involved pancuronium, 
3 vecuronium, and 1 atracurium; the neuromuscular 
blocking drugs in the other 4 cases were undeter- 
mined. Theoretically, use of pancuronium could result 
in an increase in the need for postoperative ventilatory 
support. 
Total cost of commodities per case ranged from a high 
of $116.45 in 1991 to a low of $104.83 in 1993. 
D i s c u s s i o n  
Cost containment measures initiated as part of a quality 
improvement program have decreased the cost per case 
of a number  of anesthetic drugs at the University of  
Michigan Medical Center. Previous reports have been 
made on the theoretical analysis of anesthetic costs ~ 
and the potential benefits (cost-effectiveness) of several 
drugs. 4.5 The use of older, less expensive neuromuscular 
blocking drugs and low-flow anesthesia has been thought 
to decrease costs for a number  of years. 6,7 To our knowl- 
edge, our study is the first report on the actual clinical 
efficacy of such measures. 
Despite the success at decreasing expenditures for 
pharmaceutical drugs, there are limitations to these ap- 
proaches. Without adequate instruction in low-flow anes- 
thesia, providers may risk inadequate anesthesia, 
especially at induction, or excessive anesthesia, especially 
during a lengthy case. For these reasons, implementation 
of low-flow anesthesia as a routine practice was delayed 
until the introduction of drug monitors in each room. 
The one-time cost of the new monitors was weighed 
against the potential continuing savings of low-flow anes- 
thesia, although the new monitors were scheduled to be 
purchased in any case. 
Additionally, as flows are lowered, mechanical limita- 
tions become apparent. A 100 ml /min  +'leak that is not 
noticeable at 3 L /min  flows becomes a 50% loss of deliv- 
ered gases when flows are decreased to 200 ml/min.  
Many newer anesthesia machines have minimal flow re- 
quirements for oxygen (O~) and ratio monitor/controls  
to ensure that a hypoxic mixture will not be delivered. 
These work well at flows of 1 L /min  or greater where 
02 consumption is less than 25% of total flow, but as 
closed-circuit flows are approached, even the administra- 
tion of air can result in hypoxic mixtures. 
As one approaches closed-circuit flows, the incremen- 
tal savings progressively diminish, resulting in large in- 
creases in effort for little additional advantage. For a 
3-hour case and a 70 kg patient (cardiac output = 4.8 
L/min) ,  the lower limit for cost may be as high as $13 
(or approximately 14 ml of liquid isoflurane) to maintain 
1.3 minimum alveolar concentration. This compares to 
initial costs of $19.20 and postintervention costs of  
$15.16. Therefore, despite these limitations, on average, 
decreasing flows at the Adult General Hospital resulted 
in a savings that is 50% of the way to a theoretic ideal. 
Decreasing the cost of neuromuscular blocking drugs 
also has limitations. Waste of neuromuscular blocking 
drugs is a common problem. Even at a nonuniversity 
hospital, such as Hartford Hospital in Hartford, Con- 
necticut, 25% of vecuronium may be discarded due to 
improper labeling or techniques (Dr. Linda Rice, per- 
sonal communication). Selection of which neuromuscu- 
lar blocking drug to use is limited by two factors: case 
duration and patient status. Pancuronium does not work 
well for short outpatient procedures. As the surgical pop- 
ulation becomes older and with more concurrent medi- 
cal illness, the appropriateness of the longer-acting drugs 
decreases. Even in a large university hospital setting, we 
were able to decrease neuromuscular blocking drug use 
by 38%, most likely merely by eliminating the inappropri- 
ate use of short-acting drugs. 
All savings must be weighed against the potential for 
increased anesthetic risk. Closed-circuit anesthesia has 
been demonstrated to be safe and effective.* For neuro- 
muscular blocking drugs, these savings must be weighed 
against the costs of additional care needed as a result of  
inadvertent prolonged muscle paralysis or the need for 
reintubation secondary to unrecognized residual muscle 
paralysis. This cost is not solely monetary but may involve 
increased anxiety, stress, and discomfort for the patient. 
Because of the low frequency of  reintubation as detected 
by the QA process, no difference resulting from cost 
containment measures could be detected. 
Efforts to decrease the cost per case of volatile anesthe- 
tics and neuromuscular blocking drugs may shift the cost 
*Ernst EA, MacKrell TN, Pearson JD, Cutter G, Wagenknecht L: 
Patient safety: a comparison of open and closed anesthesia circuits 
[Abstract]. Anesthedology 1987;67:A474. 
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to o ther  drugs and regional anesthetic techniques.  Tha t  
is, p ropofol  and regional block tray use may increase as 
a direct  result o f  a drive to decrease the use of  o ther  
drugs. Cost o f  commodit ies  per  case remained  relatively 
level f rom 1989 th rough  1993, ranging  f rom $116.45 in 
1991 to $104.83 in 1993. Given the effects o f  inflation, 
this f inding can be cons t rued as a reduct ion in the actual 
cost per  case. To demonst ra te  a significant reduct ion in 
our  anesthetic pha rmacy  costs (not  utilization, as costs 
were held constant  dur ing  this study), we need  to assume 
an inflation rate o f  8% per  year over the 29 months  of  
the study. This is fur ther  complicated by the fact that  
new drugs no t  studied here  (for example,  ondanse t ron)  
have been  added  to the formulary  over this time period,  
increasing costs at the same time our  cost reduct ion mea- 
sures were in place. 
Pharmaceut ical  companies  have a huge and direct  
impact  on  cost that  is outside the scope of  the anesthesiol- 
ogist's control .  As a case in point,  when the patent  on 
isoflurane expires, any decrease in cost f rom compet i t ion 
a m o n g  suppliers will decrease cost at any flow rate. From 
a medicolegal  perspective, when a d rug  is restricted (such 
as the newest r ecommenda t ions  for succinylcholine) or  
withdrawn f rom use (such as hydralazine),  usually more  
expensive alternatives must  be used. 
Educat ional  measures require much  re inforcement  
for  both  faculty and residents. Both are expected to be 
able to justify their choice o f  anesthetic technique and 
neuromuscu la r  blocking drugs with regard no t  only to 
efficacy but  also to cost-effectiveness. This justification 
takes place dur ing the preoperat ive discussion between 
the resident and the faculty and between the faculty at 
a 7 A.M. meet ing  when the day's cases are discussed. Addi- 
tionally, the authors  and others  on the team actively teach 
low-flow and closed-circuit anesthesia to demonst ra te  the 
principles o f  uptake and distribution o f  anesthetic drugs. 
O the r  benefits of  implement ing  these practices fall 
into two categories: one  involves direct  improvement  in 
pat ient  care due  to the techniques used; the o ther  in- 
volves improvement  in pat ient  care due to improved edu- 
cation. Low-flow anesthesia increases rebreathing not  
only o f  volatile anesthetic drug  but  also o f  the patient 's  
own heat  and  humidity. Therefore ,  there is less need  for 
external  devices to heat  or  humidity respiratory gases. 
There  is also less a tmospheric  pollution by these fluoro- 
carbon compounds .  
Educat ion improves the use o f  volatile anesthetics. By 
unders tand ing  uptake and distribution, residents under-  
stand how to alter the flow of  gases to change  anesthetic 
depth  rapidly. By clinicians being more  r igorous in ma- 
chine checkout ,  smaller leaks are detected.  Dur ing anes- 
thetic administration, the deve lopment  o f  smaller leaks 
is more  easily and quickly detectable. Educat ion also im- 
proves the use o f  neuromuscula r  blocking drugs. There  
should be less "ref lex" use o f  a d rug  and more  titration 
to response, individualizing each dose to the pat ient  and  
the clinical situation at hand. 
Recommenda t ions  must  be limited in scope, in par t  
because determinants  o f  cost vary by pract i t ioner and 
institution. For anesthesiologists who are already choos- 
ing low-flow anesthesia and cost-effective use o f  neuro-  
muscular  blocking drugs, the changes  in practice will be 
minimal. For those who are r unn ing  6 L / m i n  (or even 
3 L / m i n )  total flows and using vecuronium for  every 
case, the benefits could be substantial. At institutions 
where the average case durat ion is unde r  1 hour,  the 
impact  will be less because the rate o f  uptake and cost 
of  volatile anesthetics is greatest in the first minutes o f  
anesthesia and the durat ion o f  the less expensive neuro-  
muscular  blocking drugs is too long. 
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